Skip to main content

Advertisement

SpringerLink
Log in

Characteristics and prognosis of borderline ovarian tumors in pre and postmenopausal patients

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objective

To compare patient characteristics, imaging results, surgical management and prognosis of borderline ovarian tumors (BOT) between pre and postmenopausal patients.

Materials and methods

A retrospective cohort of all cases of histologically verified BOT between 1990–2018, comparing presentation, imaging, surgical procedures and recurrence. Patients were included in the postmenopausal group if they reported 12 months of amenorrhea with or without menopausal symptoms.

Results

During this 28 year study period, 66 operations were performed in which BOT was confirmed. Postmenopausal patients were 37–89 years old and premenopausal patients 18–50 years old, with an average age of 63.9 ± 13.4 and 36.2 ± 8.4 years, respectively (p < 0.001). The majority of patients in both groups were diagnosed due to abdominal pain, followed by incidental diagnosis on routine ultrasound. Imaging and CA-125 levels upon presentation were similar. Almost sixty percent of postmenopausal and 26.3% of premenopausal patients underwent laparotomy (p = 0.01), while those who underwent laparoscopy were 35.7% and 60.5%, respectively (p = 0.03). Most postmenopausal patients underwent bilateral salpingo-oophorectomy (BSO), whereas premenopausal surgeries involved cystectomy. Nearly all study patients were diagnosed in stage one. Malignant transformation occurred in 7.1% of postmenopausal patients. No malignant transformation was found in premenopausal patients.

Conclusion

BOT's present similarly in pre and postmenopausal patients. Postmenopausal patients undergo more extensive surgery, and are diagnosed in early stage disease. Despite a tendency for a more conservative approach in premenopausal patients, prognosis is similar in both groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hannibal CG, Huusom LD, Kjaerbye-Thygesen A, Tabor A, Kjaer SK. (2011)Trends in incidence of borderline ovarian tumors in Denmark 1978–2006. Acta Obstet Gynecol Scand. 90(4):305–12. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21306323

  2. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 23(1):41–4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/14668549

  3. Gilks CB. (2002) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Inter J Gynecol. 20:200–5.

  4. Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, et al. (2005) Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 24(9):S5–8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25341581

  5. Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. (2006) Conservative surgery for borderline ovarian tumors: A review Gynecologic. Oncology. 185–91. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16216320

  6. Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. (2008) Borderline ovarian tumors in Sweden 1960–2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J cancer. 123(8):1897–901. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18661518

  7. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 155(3):217–24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11821246

  8. Rizzuto I, Behrens RF, Smith LA (2013) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. John Wiley and Sons, Hoboken

    Book  Google Scholar 

  9. Mørch LS, Løkkegaard E, Andreasen AH, Kjær SK, Lidegaard Ø. (2001) Hormone therapy and ovarian borderline tumors: a national cohort study. Cancer Causes Control. 23(1):113–20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22037908

  10. Yazbek J, Raju KS, Ben-Nagi J, Holland T, Hillaby K, Jurkovic D.(2007) Accuracy of ultrasound subjective “pattern recognition” for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol. 29(5):489–95. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17444554

  11. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR (2005 Jun) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (≥5-year) follow-up. Am J Surg Pathol 29(6):707–723

    Article  Google Scholar 

  12. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C (2001 May 15) Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 19(10):2658–2664

    Article  CAS  Google Scholar 

  13. Karlsen NMS, Karlsen MA, Høgdall E, Nedergaard L, Christensen IJ, Høgdall C (2016 Jul 1) Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecol Oncol 142(1):50–53

    Article  Google Scholar 

  14. Obermair A, Tang A, Kondalsamy-Chennakesavan S, Ngan H, Zusterzeel P, Quinn M et al (2013 Feb) Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. Int J Gynecol Cancer 23(2):264–267

    Article  Google Scholar 

  15. Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS et al (2014) Risk factors for progression to invasive carcinoma in patients with borderline ovarian tumors. Int J Gynecol Cancer 24(7):1206–1214

    Article  Google Scholar 

  16. Ho C-L, Kurman RJ, Dehari R, Wang T-L, Shih I-M (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer research, Belgin

    Book  Google Scholar 

  17. Hauptmann S, Friedrich K, Redline R, Avril S (2017) Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria Virchows Archiv. Springer, London

    Google Scholar 

  18. Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK et al (2015 Aug 20) Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol 33(24):2675–2682

    Article  Google Scholar 

  19. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW et al (2012 Apr) Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause 19(4):387–395

    Article  Google Scholar 

  20. Promoting the Health of an Aging Population.(2004) Abstracts of the 57th Annual Scientific Meeting of the Gerontological Society of America. Washington, DC, USA. Gerontologist 44:1–693. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15612100

  21. Ganer Herman H, Shalev A, Ginath S, Kerner R, Keidar R, Bar J, et al. (2015) Clinical characteristics and the risk for malignancy in postmenopausal women with adnexal torsion. Maturitas. 81(1):57–61. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25804950

  22. Zacharakis D, Thomakos N, Biliatis I, Rodolakis A, Simou M, Daskalakis G, et al. (2013) Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer. Acta Obstet Gynecol Scand. 92(3):285–92. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23193945

  23. Sobiczewski P, Dańska-Bidzińska A, Rzepka J, Kupryjańczyk J, Gujski M, Bidziński M, et al. (2012) Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers. Arch Gynecol Obstet. 286(6):1513–9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22821506

  24. Morotti M, Menada MV, Gillott DJ, Venturini PL, Ferrero S. (2012) The preoperative diagnosis of borderline ovarian tumors: a review of current literature. Arch Gynecol Obstet 285(4):1103–12. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22210294

  25. Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M, Jurkovic D. (2014). Use of IOTA simple rules for diagnosis of ovarian cancer: Meta-analysis. Ultrasound Obstet Gynecol 44(5):503–14. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24920435

  26. Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C et al (2014 Oct) Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: Prospective multicentre diagnostic study. BMJ 15:349

    Google Scholar 

  27. Ureyen I, Turan T, Cirik DA, Tasci T, Boran N, Bulbul D et al (2014 Oct) Frozen section in borderline ovarian tumors: is it reliable? Eur J Obstet Gynecol Reprod Biol 1(181):115–118

    Article  Google Scholar 

  28. Basaran D, Salman MC, Calis P, Ozek A, Ozgul N, Usubütün A, et al. Diagnostic accuracy of intraoperative consultation (frozen section) in borderline ovarian tumours and factors associated with misdiagnosis. J Obstet Gynaecol 34(5):429–34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24734941. Accessed July 2014

  29. Oh S, Kim R, Lee Y-K, Kim JW, Park N-H, Song Y-S. Clinicopathological aspects of patients with recurrence of borderline ovarian tumors. Obstet Gynecol Sci. 58(2):98–105. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25798422. Accessed Mar 2015

  30. Shim SH, Kim SN, Jung PS, Dong M, Kim JE, Lee SJ (2016) Impact of surgical staging on prognosis in patients with borderline ovarian tumours: A meta-analysis. Eur J Cancer. 54:84–95. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26735354. Accessed Feb 2016

  31. Ureyen I, Karalok A, Tasci T, Turkmen O, Boran N, Tulunay G, et al. The Factors Predicting Recurrence in Patients With Serous Borderline Ovarian Tumor. Int J Gynecol Cancer [Internet]. 2016 Jan 1 [cited 2020 Apr 16];26(1):66–72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26512785. Accessed Jan 2016

  32. Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, et al. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer. 112(4):660–6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25562434. Accessed Feb 2015

  33. Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, et al. (2016) Management of borderline ovarian tumors based on patient and tumor characteristics. Gynecol Obstet Invest 81(2):169–73. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26067608. Accessed Mar 2016

  34. Song T, Lee Y-Y, Choi CH, Kim T-J, Lee J-W, Bae D-S, et al. (2015) Borderline ovarian tumor in women aged ≥ 65 years: impact on recurrence and survival. Eur J Obstet Gynecol Reprod Biol. 184:38–42. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25463633. Accessed Jan 2015

Download references

Funding

This study was not funded.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Edith Wolfson Medical Center. Holon, Affiliated With Sackler Faculty of Medicine, Tel Aviv University, 39040, Tel Aviv, Israel

    Ori Tal, Hadas Ganer Herman, Ohad Gluck, Tally Levy, Ram Kerner, Jacob Bar & Ron Sagiv

Authors
  1. Ori Tal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hadas Ganer Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ohad Gluck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tally Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ram Kerner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jacob Bar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ron Sagiv
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

O. Tal: Manuscript writing, data collection, protocol development, H. Ganer Herman: Data collection, data analysis, manuscript editing, O. Gluck: Data analysis, manuscript editing, T. Levy: Data management, manuscript editing, R. Kerner: Data management, manuscript editing, J. Bar: Data management, manuscript editing, R. Sagiv: Project development, manuscript editing.

Corresponding author

Correspondence to Ori Tal.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by our institutional ethical review board. As this study is based on encrypted data analysis only, informed consent was not needed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tal, O., Ganer Herman, H., Gluck, O. et al. Characteristics and prognosis of borderline ovarian tumors in pre and postmenopausal patients. Arch Gynecol Obstet 302, 693–698 (2020). https://doi.org/10.1007/s00404-020-05652-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-020-05652-w

Keywords

Search

Navigation